Brought to you by 
Celularity raises $250mm in Series A round
14 Nov 2022
Executive Summary
Regenerative medicine start-up Celularity Inc. raised $250mm in Series A funding from Celgene, United Therapeutics, Sorrento Therapeutics, Human Longevity, Genting Group, the Dreyfus Family Office, Section 32, and Heritage Group.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celularity raises $250mm in Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice